Answers are grounded in this paper and cite their sources.
The stu dy was planned to evaluate pharmacokinetic profile and in vivo anti-inflammatory property of rutin following intramuscular administration (100 mg/kg, intramuscular) in rats.Carrageenan-induced paw edema assay was carried out separately to study in vivo anti-inflammatory property of rutin.The plasma rutin concentration was assayed using High Performance Liquid Chromatography (HPLC).The pharmacokinetic parameters like the maximum plasma drug concentration (C max ), time for maximal concentration (T max ), elimination half-life (t ½ ), apparent volume of distribution (Vd (area) ), total body clearance (Cl (B) ) and mean residence time (MRT) were 21.11 0.46 g/ml, 1.83 ± 0.17 h, 9.11 1.50 h, 16.34 2.32 l/kg, 1.27 0.04 l/h/kg and 4.79 0.55 h, respectively.The drug concentration of 0.21 0.02 g/ml in plasma was detected at 24 h.In carrageenan-induced paw edema assay, rutin (100 mg/kg) significantly decreased edema volume from 1 to 6 h in comparison to carrageenan group and vehicle group.Per cent inhibition of inflammation after 6 h of rutin administration was 29.94 ± 1.49.Intramuscular administration of rutin produced satisfactory pharmacokinetic profile with promising in vivo anti-inflammatory activity in rats.
No takes yet. Share an insight, caveat, or question.
Modi et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: